In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: Implications for drug mechanisms of action
- 1 December 1986
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 39 (26) , 2571-2580
- https://doi.org/10.1016/0024-3205(86)90111-6
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Treatment of acute psychosis with non-neuroleptic agentsPsychosomatics, 1986
- Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitroEuropean Journal of Pharmacology, 1984
- Characterization of α1-and α2-Adrenergic ReceptorsPublished by Elsevier ,1983
- Brain catecholamines in schizophrenia — a good case for noradrenalineNature, 1982
- Receptor Adaptations to Centrally Acting DrugsAnnual Review of Pharmacology and Toxicology, 1981
- Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potencyAmerican Journal of Psychiatry, 1980
- Clinical use of the radioreceptor assay for neurolepticsPsychiatry Research, 1980
- Modulation of receptor mechanisms in the CNS: Hyper-and hyposensitivity to catecholaminesNeuropharmacology, 1978
- Antipsychotic Drugs, Neurotransmitters, and SchizophreniaAmerican Journal of Psychiatry, 1978
- Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholaminesNeuropharmacology, 1974